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Science in medicine

Molecular processes that handle —
and mishandle — dietary lipids
Kevin Jon Williams
Division of Endocrinology, Diabetes, and Metabolic Diseases, Department of Medicine,
Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Overconsumption of lipid-rich diets, in conjunction with physical inactivity, disables and kills
staggering numbers of people worldwide. Recent advances in our molecular understanding of
cholesterol and triglyceride transport from the small intestine to the rest of the body provide
a detailed picture of the fed/fasted and active/sedentary states. Key surprises include the unexpected nature of many pivotal molecular mediators, as well as their dysregulation — but possible
reversibility — in obesity, diabetes, inactivity, and related conditions. These mechanistic insights
provide new opportunities to correct dyslipoproteinemia, accelerated atherosclerosis, insulin
resistance, and other deadly sequelae of overnutrition and underexertion.
Introduction
Why has intestinally absorbed lipid remained the focus of clinical
and basic efforts spanning at least a century (1)? Because absorption of dietary essential fatty acids and lipid micronutrients by
the small intestine sustains human life, but at the same time, the
capacity of this organ to absorb our flagrantly lipid-rich modern
diet maims and kills people. It does so in at least 3 major ways.
First, intestinally derived lipoproteins, chiefly chylomicrons
(CMs), transport calorie-dense triglycerides to adipose depots (2,
3), accelerating the development of obesity (2) and its many harmful sequelae. Second, while delivering triglycerides to peripheral
tissues, CMs become processed into so-called CM “remnants”
that carry significant amounts of cholesterol. These remnant particles, particularly the smaller ones (4), enter the arterial wall and
are retained there (5), initiating and promoting the development
of atherosclerotic plaques (6). Third, CMs and their remnants
interfere with the catabolism of harmful hepatic lipoproteins (7,
8) that are also retained within the vessel wall, promoting atherogenesis (6, 9–12). Postprandial dyslipidemia, which refers to
the abnormal persistence of intestinal and hepatic lipoproteins
in plasma after each meal, makes a substantial — and potentially
avoidable — contribution to the population-wide burden of atherosclerotic cardiovascular disease, particularly in diabetes and
related conditions (4, 13). Atherosclerosis kills roughly half of
individuals living in Westernized countries and 30% of people
worldwide, making it easily the most deadly human disease (14).
The overfed intestine drives much of the problem.
This review follows the path of dietary and biliary lipid once it
enters the lumen of the small intestine (Figure 1). The focus is lipid
macronutrients, chiefly triglycerides and cholesterol, because they
are causally linked to death and disability from obesity and cardiovascular disease. Nonlipid calories are not covered, although their
Nonstandard abbreviations used: ABC, ATP-binding cassette transporter; ACAT2,
acyl-CoA:cholesterol acyltransferase–2; CM, chylomicron; DGAT, acyl-CoA:diacylglycerol acyltransferase; GPI, glycosylphosphatidylinositol; GPIHBP1, GPI-anchored HDLbinding protein 1; HSPG, heparan sulfate proteoglycan; LpL, lipoprotein lipase; MTP,
microsomal triglyceride transfer protein; NEFA, nonesterified fatty acid; NPC1L1,
Niemann-Pick C1–like 1 protein; UC, unesterified cholesterol.
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effects on lipid and lipoprotein biology can be found elsewhere (8,
15). Strikingly, the molecular responses to obesity, insulin resistance, physical inactivity, and related conditions paradoxically
enhance intestinal CM production, direct CM triglycerides away
from combustion in striated muscle and toward storage in adipose
tissue, and worsen atherogenic postprandial dyslipidemia (Table
1). Nevertheless, most, if not all, of these points of molecular dysregulation may be reversible.
Facilitated absorption of cholesterol: from drug to target
The major recent breakthrough in understanding cholesterol
absorption by the small intestine arose from the discovery of
ezetimibe, a medicine that blocks this pathway (16). Notably, the
medicine was found via low-throughput screens in whole animals;
moreover, it was FDA approved and on the market for years before
its molecular target was identified. Ezetimibe provides a compelling counterexample against the prevailing postgenome paradigm
for drug discovery, dubbed conveyor belts, in which high-throughput screens of compounds against known protein targets lead to
FDA-approved medicines.
Despite some initial controversy (17, 18), it is clear that the target
of ezetimibe is the Niemann-Pick C1–like 1 protein (NPC1L1; refs.
17, 19). The NPC1L1 protein is highly expressed in small intestine
(19) and in human liver (20), precisely where the drug acts. Ezetimibe glucuronide binds to a single, saturable site on wild-type
enterocyte brush border membranes and to cells expressing recombinant NPC1L1 (17). Enterocyte membranes from Npc1l1–/– mice
show no ezetimibe binding (17), and Npc1l1-deficient mice exhibit
an approximately 70% reduction in cholesterol absorption that
cannot be lowered further by administration of ezetimibe (19). In
humans, NPC1L1 gene variants correlate with sterol absorption
(21), baseline plasma LDL concentrations (21), and responsiveness
of LDL levels to ezetimibe administration (18). Moreover, most
human NPC1L1 variants associated with inefficient intestinal
cholesterol absorption exhibit substantial impairments in protein
expression, consistent with the phenotype (21).
Physiologic regulation of NPC1L1 alters cholesterol absorption in response to availability, apparently through a sterol-regulatory element in the promoter and a sterol-sensing domain
in the protein. Cholesterol-rich diets suppress Npc1l1 expres-
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Figure 1
Overview of lipid transport from gut lumen to periphery to liver. Detergents in hepatic bile, chiefly phospholipids (PL) and bile acids, emulsify lipids
from food to form microscopic micelles within the gut lumen. Hepatic bile also contributes significant amounts of UC to these micelles. The pancreas secretes lipases that digest dietary lipids into chemical forms that can be absorbed by the gut epithelium, e.g., NEFAs, monoacylglycerides,
and UC. Absorption of fatty acids and monoacylglycerides approaches 100% efficiency and occurs via passive diffusion and carrier-mediated
processes (64). Cholesterol absorption averages about 50% efficiency with considerable interindividual variation. Enterocytes reesterify these
lipids intracellularly and then package them into large particles, CMs, that are rich in triglycerides (TG) but also contain substantial amounts of
UC and cholesteryl esters. These particles are secreted into thoracic lymph, which drains directly into the systemic bloodstream, bypassing the
liver. The mixed lipid composition of CMs leads to a 2-step clearance process. First, when these particles reach the capillary beds of peripheral
tissues, a key metabolic branch point occurs between energy storage in adipose tissue (blue arrows) and lipid combustion in striated muscle
(green arrows). In a regulated fashion, CMs dock on the microvascular endothelium of these tissues, where LpL hydrolyzes CM triglycerides
into NEFAs to deliver lipid calories for local use. In the second step of clearance, residual triglyceride-depleted, cholesteryl ester–rich particles,
now called CM remnant lipoproteins, are released back into plasma. Under normal circumstances, the liver rapidly and safely removes them
from the circulation (red arrows).

sion in murine intestine, and cholesterol depletion enhances its
expression in porcine intestine and liver (18). Posttranslationally, NPC1L1 moves from internal membranes into the plasma
membrane during cholesterol deprivation, facilitating absorption (22). These studies of translocation might reconcile reports
that Npc1l1 is (19) or is not (23) found in the enterocyte brush
border. Consistent with translocation, the predominant effect of
NPC1L1 appears to be the facilitated trafficking of unesterified
cholesterol (UC) from the plasma membrane into the ER, where
the lipid becomes esterified and packaged into nascent lipoproteins (Figure 2 and ref. 24). In contrast, the effect of NPC1L1 on
cholesterol movement into the plasma membrane from exogenous sources is modest (24).
3248
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The NPC1L1 protein exerts major effects on the transport
of dietary and nondietary cholesterol within the gastrointestinal system. Even in individuals consuming a lipid-rich modern diet, more than two-thirds of the cholesterol that enters
the gut lumen comes from bile (Figure 1 and ref. 21). Thus, by
blocking NPC1L1 in the intestine, ezetimibe not only impairs
absorption of dietary cholesterol, but also depletes cholesterol
from the enterohepatic circulation. Liver cholesterol content
drops, an effect augmented clinically by coadministration of
statins. Consequences include a slight impairment in hepatic
VLDL secretion and a substantial induction of sterol-responsive genes in the liver, particularly that encoding the LDL receptor (18). These effects lower plasma LDL levels by 15%–20%.

http://www.jci.org

Volume 118

Number 10

October 2008

science in medicine
Table 1
Dysregulated mediators of lipid and lipoprotein trafficking in diabetes, obesity, and related conditions
Molecule/process

Dysregulation

Likely consequences

NPC1L1, ABCG5/G8

In diabetes, increased intestinal and hepatic
expression of Npc1l1 (28) and decreased
intestinal expression of ABCG5/G8 (28–30)
MTP
Intestinal overexpression in intestinal
insulin resistance (15) and diabetes (28, 30)
Intestinal lipid synthesis
Increased synthesis of fatty acids, triglycerides,
and cholesteryl esters by enterocytes
in intestinal insulin resistance (15)
LpL
Increased activity in adipose tissue, but decreased
activity in striated muscle, in the fed
and sedentary states (3, 78, 79)
Angiopoietin-like proteins
Suppressed expression in adipose
tissue in the fed state (84)
Mitochondrial β‑oxidation
Reduced capacity in sedentary skeletal muscle (86)
		
Gpihbp1
Suppression of its mRNA in muscle in the fed state (90)
		
CD36 fatty acid translocase
Increased expression in adipose tissue in diabetes (103)
Ndst1
Suppressed mRNA, protein, and enzymatic
activity in diabetic liver (122)
		

Increased intestinal cholesterol absorption, decreased
hepatic biliary cholesterol excretion, and increased
cholesterol content of secreted CMs and VLDL
Substantially increased intestinal secretion of apoB48,
hence an increased number of secreted particles
Increased CM secretion in insulin
resistance and overt diabetes (67)
Diversion of CM and VLDL calories into
adipose depots for storage and away
from combustion in muscle
Diversion of CM and VLDL calories into adipose depots
owing to a local increase in enzymatically active LpL dimers
Accumulation of triglycerides and fatty acid
metabolites, leading to insulin resistance in muscle
Diversion of CM and VLDL calories away
from combustion in muscle
Enhanced adipose uptake of calories in the form of NEFAs
Defective hepatic assembly of HSPGs,
hence abnormal persistence of atherogenic
postprandial remnant lipoproteins in plasma

Ndst1, heparan sulfate N-deacetylase/N-sulfotransferase–1.

In transgenic mice, ezetimibe also blocks NPC1L1 within the
liver, thereby allowing endogenous cholesterol to exit into bile
rather than being taken back up into hepatocytes for secretion
into plasma (25). Because human liver abundantly expresses
NPC1L1 (20), clinical administration of ezetimibe might also
increase cholesterol elimination into bile (25). Thus, blockage
of NPC1L1 augments the ability of the gastrointestinal system
to dispose of dietary and nondietary cholesterol. For example,
reverse transport of cholesterol, from lipid-loaded peripheral
macrophages to HDL to the liver, then into bile and out into
the feces, becomes more efficient in ezetimibe-treated mice,
owing to inhibition of intestinal reabsorption of HDL-derived
biliary cholesterol, but without any apparent effects on macrophages or on HDL particles (26, 27).
Regarding dyslipidemias, type 1 diabetic rats show increased
Npc1l1 expression in both intestine and liver, and the levels correlate, respectively, with CM and VLDL cholesterol content (Table
1 and ref. 28). This finding may contribute to cholesterol hyperabsorption in human type 1 diabetes (29). Type 2 diabetes also
increases intestinal NPC1L1 mRNA in humans (30), and among
type 2 diabetic patients, those with coronary artery disease absorb
cholesterol more efficiently than those without (31). Compared
with nondiabetic controls, however, type 2 diabetic subjects exhibit increased intestinal cholesterol synthesis, not absorption (29).
In the other direction, genetic deficiency of Npc1l1 in the apoE
knockout mouse, an animal model that accumulates remnantlike lipoproteins in its plasma, lowers the cholesterol content of
atherogenic lipoproteins by 80%–90% and blocks the development of vascular disease (32). Regarding human atherosclerosis,
long-term studies to examine the effectiveness of ezetimibe on
cardiovascular outcomes must still be completed, even though
nearly every strategy to lower plasma LDL levels has resulted in
The Journal of Clinical Investigation

essentially the same degree of long-term cardiovascular protection (11). A 2-year study in familial hypercholesterolemic subjects
failed to find a significant effect of this medicine on carotid intimal-medial thickness (33).
Surprisingly, the expression of NPC1L1 by enterocytes also
facilitates uptake of toxic, noncholesterol sterols from plants,
shellfish, and other dietary sources (17, 18). The ability of the
normal intestine to selectively prevent these molecules from
moving into the rest of the body was recognized decades ago
with the discovery of β-sitosterolemia, a rare recessive disease
in which plant sterols accumulate systemically. The responsible
mutations reside in either of 2 ATP-binding cassette transporters (ABCs), ABCG5 and ABCG8 (34). These proteins are actually half-transporters that form heterodimers (35) that pump
nearly all noncholesterol sterols out of the enterocyte, back into
the gut lumen for excretion in feces (Figure 2 and ref. 34). The
ABCG5/G8 transporter also pumps some cholesterol out of
enterocytes (34), thereby explaining cholesterol hyperabsorption in β-sitosterolemia. Suppression of ABCG5/G8 in type 1
diabetic intestine may also contribute to cholesterol hyperabsorption (Table 1 and refs. 28, 29).
Dimers of Abcg5/g8 are also expressed in liver, where they
cooperate with Abcb4 (also known as Mdr2) to pump UC and
phospholipid into bile (34), while hepatic NPC1L1 transports
UC from bile back into the hepatocyte (25). The combined effects
of these 4 proteins regulate biliary cholesterol content before
its release into the intestinal lumen. Both Abcg5 and Abcg8 are
liver X receptor (Lxr) targets and are induced by high-cholesterol diets. Lxr agonists enhance intestinal cholesterol excretion
through these transporters (36); but, as side effects, these agonists also induce lipid biosynthesis and steatosis in the liver as
well as apoptosis of pancreatic β cells.
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Figure 2
Processing of dietary lipid by the enterocyte: absorption, selection, packaging, and secretion. In the apoB-dependent pathway (black arrows),
apoB48 becomes assembled in the ER with initially small amounts of triglycerides that are synthesized mainly by DGAT2 and transferred via MTP.
UC imported from the gut lumen into the enterocyte via NPC1L1 and possibly other proteins becomes esterified by ACAT2 and also packaged
into the newly forming apoB48 lipoprotein. Continued lipidation in the ER inflates the particle, requiring stabilization of its surface by phospholipids
and apoA-IV. The nascent particles are then transferred to the Golgi apparatus in noncanonical transport vesicles, further lipidated, and finally
secreted as CMs into lymph. Some of the absorbed cholesterol and essentially all of the dietary noncholesterol sterols are pumped out of the
enterocyte, back into the intestinal lumen for elimination from the body (blue arrows). In the apoB-independent pathway (green arrows), UC is
absorbed into the enterocyte, and then ABCA1 facilitates its efflux from the plasma membrane onto extracellular apoA-I molecules. Movement
onto preexisting extracellular HDL also occurs. The apoA-I originates both from local intestinal synthesis and from plasma. Absorption of NEFAs,
monoglycerides, and lipid micronutrients across the brush border and esterification by acyl-CoA:monoacylglycerol acyltransferase enzymes are
not shown here. CE, cholesteryl ester; PC, phosphatidylcholine; Sito, sitosterol and other noncholesterol sterols.

Intestinal packaging of absorbed lipids into
apoB48-containing lipoproteins
Similarities to hepatic production of apoB100-containing lipoproteins
A key structural component of CMs is the huge, hydrophobic,
nonexchangeable protein apoB, which exists in 2 forms in the
body. Human liver makes full-length apoB100, the major protein
of hepatically derived atherogenic lipoproteins (e.g., VLDL and
LDL). The C terminus of apoB100 contains the domain recognized
by the LDL receptor, thereby mediating high-affinity clearance of
these particles from plasma. In contrast, essentially all of the apoB
from human intestine appears as a truncated form, apoB48, that is
missing the C-terminal 52% (37), and so CMs and CM remnants
rely on exchangeable proteins, particularly lipoprotein lipase
(LpL; refs. 38–41), hepatic lipase (42, 43), and apoE (44–46), to
serve as ligands for cell surface receptors. Polymorphisms of each
of these exchangeable proteins affect fasting lipoprotein concentrations (47) and the postprandial response (43). Intestinal apoB48
3250
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comes from the same gene as apoB100 through the action of the
APOB mRNA editing complex–1 (APOBEC1), which deaminates
a single cytidine into a uridine, thereby creating a nongenomic inframe stop codon (UAA) roughly in the middle of the RNA coding
region (Figure 2 and ref. 48).
Far more details are known about the cellular processes in
the liver that allow this huge, hydrophobic protein to become
cotranslationally and posttranslationally assembled with lipids
(49) and what regulates its subsequent secretion (50). Both intestine and liver depend on acyl-CoA:diacylglycerol acyltransferases
(DGATs) and acyl-CoA:cholesterol acyltransferase–2 (ACAT2)
for intracellular synthesis of triglycerides and cholesteryl esters
that will be assembled into the hydrophobic cores of nascent
apoB-containing lipoproteins (Figure 2). Both organs require the
microsomal triglyceride transfer protein (MTP) to shuttle small
amounts of triglyceride onto each newly forming apoB molecule
as it translocates into the ER lumen, thereby allowing proper folding of the protein. A second lipidation step later in the secretory
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pathway occurs in enterocytes (51) and in hepatocytes (52, 53) to
generate large CMs and VLDL, respectively. In hepatocytes, extensive lipidation of nascent apoB lipoproteins requires a motif that
is present in both apoB48 and apoB100 (53), but a role for this motif
has not yet been reported in enterocytes. Fully assembled apoB
lipoproteins are released by exocytosis of secretory vesicles from
the basolateral membrane of enterocytes (Figure 2).
Genetic deficiency or pharmacologic inhibition of MTP allows continued synthesis of apoB (49, 54), but the misfolded protein becomes
destroyed by ER-associated degradation (ERAD), a process mediated
in cultured hepatocytes by the proteasome (49). The same mechanism is presumably at work in MTP-deficient enterocytes. Genetic
lack of MTP causes abetalipoproteinemia, a heritable condition characterized by the complete absence of apoB48 and apoB100 lipoproteins
from plasma, as well as the development of intestinal and hepatic steatosis, malabsorption, and deficiencies of fat-soluble vitamins (55).
Unfortunately, the side effects of fatty intestine and liver hamper the
use of pharmacologic inhibitors of MTP to lower plasma apoB lipoprotein levels in humans (56). However, in unmanipulated intestinal
cells (54) and in normal primary hepatocytes (57), ERAD appears to
have little or no role in the physiologic regulation of apoB secretion.
Fatty meals induce Mtp expression in normal enterocytes, presumably to facilitate lipid absorption and packaging (58).
In collaboration with the Fisher laboratory, my colleagues and
I identified 2 new processes that regulate apoB secretion from
cultured hepatocytes and from liver in vivo: post-ER presecretory
proteolysis (50, 57, 59) and reuptake (39, 50, 60), both of which
could be active in intestine. Post-ER presecretory proteolysis is of
particular interest, given our finding that polyunsaturated Ω-3 fatty
acids from fish oils preferentially inhibit hepatic secretion of large
apoB lipoproteins via this mechanism (50). Chronic administration
of these same fatty acids blunts postprandial hypertriglyceridemia
in humans via decreased CM production (61).
Unique features of intestinal production of apoB48-containing
lipoproteins
The intestine has a unique need to rapidly assemble and secrete
gigantic CM particles to carry large amounts of newly absorbed
triglycerides. Several adaptations have been identified, the first
of which is apoB48 itself. Comparisons of wild-type and Apobec1–/–
mice, which cannot edit intestinal Apob mRNA, revealed that the
short form of apoB assembles more efficiently into CMs than does
apoB100, particularly after a lipid-rich meal (48). To quickly export
triglycerides after dietary absorption, the intestinal mucosa appears
to keep a preformed supply of apoB48 in reserve that becomes lipidated into large CMs as needed (62). Recruitment of apoB48 from
this preformed pool may involve MTP. Accordingly, a substantial
increase in apoB48 secretion occurs in conditions with abnormally high intestinal MTP expression. Examples include the –493T
human MTP promoter polymorphism (43), intestinal insulin resistance (15), and overt diabetes (28, 30).
Fat feeding also provokes marked intestinal expression of an
amphipathic protein, apoA-IV, that serves as a surface component for the rapidly inflating apoB48 particles within the enterocyte (Figure 2 and refs. 63, 64). Once CMs reach the bloodstream,
apoA-IV becomes displaced by apoCs and apoE as a prelude to
lipolysis and clearance. A common apoA-IV variant that exhibits
higher lipid affinity, Q360H, has been associated with increased
postprandial hypertriglyceridemia, presumably by impeding this
transfer of apoCs and apoE onto CMs (63).
The Journal of Clinical Investigation

CMs vastly exceed the size of canonical ER-to-Golgi transport
vesicles, which are only 60–70 nm in diameter (65). In hepatocytes,
2 adaptations have been reported: slightly larger transport vesicles of about 100 nm and the release of consistently small, dense
apoB100 particles from the ER regardless of lipid availability (52).
Several lines of evidence, however, indicate that intestinal adaptations possess distinct features. First, the enterocyte performs considerable lipidation of apoB48 particles in the ER, and as a consequence, the ER-to-Golgi transport vesicles have been reported to
average about 250 nm in diameter (64), over 50 times the volume
of canonical transport vesicles (Figure 2). Second, to create and
then target these unusual transport vesicles, the enterocyte reportedly uses a unique set of proteins. Instead of depending on coat
proteins (COPII) for ER budding, the enterocyte apparently relies
on intracellular fatty acid–binding protein–1 (Fabp1), and perhaps
Fabp2, to create apoB48 transport vesicles (64). Of note, the A54T
polymorphism of FABP2 associates with increased postprandial
lipemia (43). Third, a rare inherited syndrome, CM retention disease, preferentially affects the intracellular transport and secretion of apoB48 lipoproteins from enterocytes while still permitting
secretion of apoB100 particles from liver. Patients exhibit malabsorption, fat-filled enterocytes, no plasma apoB48, no postprandial
CMs, present but decreased plasma levels of apoB100 lipoproteins,
and low HDL levels. Jones et al. (65) and others (66) linked this
syndrome with several mutations in the SAR1B protein, a GTPase
involved in the budding of canonical COPII-coated vesicles from
the ER. In hepatocytes, Sar1 proteins are required for these apoBcontaining vesicles to bud off the ER (52). In an enterocyte system,
however, blockage of Sar1 still allowed the generation of apoB48
transport vesicles, presumably in the context of continued activity of intracellular Fabp1 and Fabp2, but these abnormal vesicles
failed to fuse with the Golgi complex (64). Based on these differences, it is possible that SAR1B mutations in CM retention disease
allow budding, transport, and Golgi fusion of apoB-containing
vesicles in hepatocytes but interfere with these processes, particularly Golgi fusion, in enterocytes. This overall cellular and molecular understanding has led to several strategies to inhibit apoBdependent absorption of lipids from the gut lumen, some under
exploration in vivo and others already in clinical use (Table 2).
Because human liver makes no apoB48 and human intestine synthesizes no detectable apoB100 (37), the type of apoB identifies the origin of an atherogenic human lipoprotein. Each of these lipoproteins
contains exactly 1 molecule of apoB, and so the mass of apoB48 or
apoB100 is used to estimate particle number. After a fatty meal, roughly 80% of the rise in plasma triglyceride concentration in humans is
carried by apoB48 lipoproteins, chiefly large CMs, but about 80% of
the increase in particle count comes from apoB100 lipoproteins (8).
The comparatively low number of apoB48 particles has led some
authors to propose that the effects of intestinal apoB48 lipoproteins
on vascular disease are largely indirect, brought about by their ability
to increase the concentration and atherogenicity of apoB100 lipoproteins and to lower plasma HDL levels (7, 8). In intestinal insulin resistance and overt diabetes, the increase in apoB48 secretion noted above
implies a higher particle number. Insulin resistance also enhances
endogenous intestinal synthesis of fatty acids, triglycerides, and cholesteryl esters that contribute to CM overproduction (15, 67) and
downstream atherogenic effects (Table 1 and ref. 7).
The intestine also mediates several pathways for lipid absorption that do not depend on apoB. For example, some cholesterol
absorption occurs via HDL and its major protein, apoA-I (Figure 2
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Table 2
Pharmacologic strategies to inhibit apoB-dependent absorption of lipids from the gut lumen
Target and strategy

Rationale

Additional NPC1L1 inhibitors
Pancreatic lipase inhibitors
MGAT2 inhibition
DGAT1 inhibition
ACAT2 inhibition
MTP inhibition

Reduced intestinal absorption of biliary and dietary cholesterol, particularly in the
subset of poor responders to the currently available NPC1L1 inhibitor ezetimibe
Impaired digestion and absorption of dietary triglycerides; better adherence to low-fat diets owing
to abdominal discomfort after eating oils that cannot be absorbed; agents are in clinical use
Impaired reassembly of triglycerides within the enterocytes, which could impede CM assembly
Dgat1–/– mice exhibit reduced postprandial chylomicronemia, increased energy expenditure, and resistance
to obesity, all of which would be desirable characteristics; conversely, Dgat2–/– mice die as neonates
Reduced assembly of cholesteryl esters into CMs and VLDL
Impaired assembly and secretion of apoB lipoproteins by intestine and liver

MGAT2, acyl-CoA:monoacylglycerol acyltransferase–2.

and ref. 68). Accordingly, knockout of apoA-I (68) or its receptor,
Abca1 (69), impairs apoB-independent cholesterol absorption. The
role of NPC1L1 in this process has not yet been examined, but it is
unlikely that shuttling of UC into the ER and then esterification
by ACAT2 would be required (Figure 2). Absorption of mediumchain triglycerides also occurs independently of apoB. The lipids
are hydrolyzed in the gut lumen and absorbed directly into portal blood as nonesterified fatty acids (NEFAs) in a process that
may involve apoA-IV (70). These apoB-independent pathways are
exploited to treat deficiencies in essential fatty acids and fat-soluble vitamins that develop in patients with abetalipoproteinemia or
CM retention disease. The regimes involve administration of lowfat diets supplemented with medium-chain triglycerides, as well as
high oral doses of fat-soluble vitamins that the intestine can then
incorporate into lipoproteins resembling HDL. Lastly, proteins
other than apoB mediate each step in the reabsorption of bile acids
by the terminal ileum. Efficient transport of bile acids from the gut
lumen into ileal enterocytes occurs via the apical Na+-dependent
bile acid transporter and via Na+-independent organic anion transporting peptides (71). Clinically available bile acid sequestrants, as
well as new investigational agents that inhibit bile acid transporters, deplete the enterohepatic circulation of bile acids by blocking
ileal reabsorption. In response, the liver increases bile acid synthesis, a process that consumes hepatic cholesterol, stimulates LDL
receptor expression, and thereby lowers plasma LDL levels.
CM catabolism: branch point between storage and
combustion
Regulated hydrolysis of CM triglycerides
Enzymatically active dimers of LpL bound to the capillary endothelium of adipose tissue and striated muscle hydrolyze the
triglycerides of CMs and VLDL, releasing NEFAs for local and systemic use (Figure 1; reviewed in refs. 72, 73). Hydrolysis by LpL
converts CMs into smaller, cholesteryl ester–rich remnant lipoproteins that are released back into the bloodstream. Studies in vitro
established heparan sulfate proteoglycans (HSPGs) on the surface
of cultured endothelial cells as tethering molecules for LpL (72).
Each HSPG molecule consists of a protein core onto which the cell
has assembled highly negatively charged sugar polymers, called
heparan sulfate, that bind positively charged domains on numerous proteins, including LpL (for a brief primer on proteoglycan
biology, see ref. 74). Mutations in LpL and its cofactor, apoC-II, are
3252
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responsible for certain rare familial chylomicronemias, confirming
in humans that these molecules are rate limiting in CM catabolism
(73, 75). Human polymorphisms of 2 LpL inhibitors, apoC-III and
apoA-II, correlate with altered postprandial lipoprotein metabolism (43). Capillary endothelium does not make LpL, but instead
picks it up from underlying adipocytes and striated muscle cells
(73). Studies in vitro indicate that transcytosis of the enzyme for
display on the luminal side is mediated by basolateral HSPGs acting in concert with the VLDL receptor (Figure 3 and ref. 76).
Because LpL is rate limiting, this system provides a crucial
metabolic branch point between storage of CM calories in adipose tissue and combustion in striated muscle (Figures 1 and 3).
Targeted overexpression of LpL in muscle prevents diet-induced
obesity in mice, apparently by diverting CM lipolysis away from
fat and into muscle (77). Likewise, a targeted deficiency of LpL in
adipose tissue ameliorates obesity in hyperphagic mice (2). Formal energy balance studies in these mice would be of interest.
Similar phenomena occur physiologically in humans: differential
regulation of LpL activity in fat versus striated muscle diverts
triglycerides to adipose tissue in the fed and sedentary states,
but to muscle during fasting (3, 78) or exercise (79) (Figure 1).
These molecular processes likely contribute to the strong correlation between obesity and the tendency to sit (79, 80) and overeat
(81) (Table 1). Published data on the relevant points of control
show considerable complexity (3) and include regulation of LPL
mRNA transcription, LPL mRNA stability, LpL protein synthesis, maturation in the ER (82), glycosylation, posttranslational
degradation of LpL via its binding to HSPGs on the surface of
adipocytes (83) and myocytes, and posttranslational disruption
of enzymatically active LpL dimers by angiopoietin-like proteins
(47, 84), which are themselves regulated by feeding, fasting,
nuclear receptor ligands, and gut microbiota (Table 1 and refs.
84, 85). Despite the regulation of LpL, NEFAs can be delivered
to skeletal muscle in excess of its capacity for β-oxidation, particularly in the context of obesity and physical inactivity (86).
Subsequent accumulation of triglycerides within myocytes may
cause insulin resistance (86, 87), a situation that can be corrected
in animals by exercise (Table 1 and ref. 88).
A conceptual difficulty, solved by 2 unexpected participants
The liver also contains HSPGs and, in the fed state, LpL (reviewed
in refs. 39, 40). This presents a conceptual difficulty: How do CMs
avoid hepatic clearance before their conversion into remnant
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Figure 3
Integrated model of CM binding and hydrolysis on peripheral capillary endothelium. Adipose tissue and striated muscle each synthesize LpL,
regulated by the fasted/fed and active/sedentary metabolic states. HSPGs on the surfaces of these cells capture and internalize LpL for degradation. LpL that escapes degradation will be picked up by HSPGs and VLDL receptors on the basal surface of overlying endothelial cells for
transcytosis to the luminal surface of capillaries (orange arrows). Heparan sulfate side-chains of syndecan and glypican are denoted by chains
of small spheres. The major HSPGs of endothelium, syndecans and glypicans, move into detergent-insoluble membrane microdomains (rafts)
rich in caveolin-1 (CAV1) upon clustering. On the apical surface, they encounter GPIHBP1, which should also move into rafts upon clustering.
The highly negatively charged N-terminal domain of GPIHBP1 binds LpL with approximately 10-fold greater affinity than do endothelial HSPGs.
Thus, after transcytosis, LpL should be torn away from syndecans and glypicans onto GPIHBP1 (pink arrows). Dimers of GPIHBP1 bind LpL and
CMs, thereby providing a platform for CM docking and triglyceride lipolysis. These processes are facilitated by apoC-II and apoA-V. Lipolysis
generates NEFAs that are transported by another raft molecule, CD36, across the endothelium and into adipocytes for energy storage (blue
arrows) or into striated myocytes for combustion (green arrows). After hydrolysis of CM triglycerides, the endothelium releases apoB48 remnant
lipoproteins that are rich in LpL, apoE, and cholesteryl ester back into the circulation (red arrow). Under normal circumstances, these remnant
particles undergo safe, swift uptake by the liver.

lipoproteins? In fact, the heparan sulfate chains in liver exhibit
extreme structures of high flexibility and negative charge (89), and
hence show far stronger ligand affinity than does heparan sulfate
in other tissues, including peripheral endothelium. Thus, injection of LpL or other heparin-binding proteins results in primarily hepatic clearance, with little if any delivery into fat or muscle.
Direct hepatic uptake of CMs may be diminished by their secretion
from the intestine into lymph, which bypasses the portal circulation (Figure 1). A common explanation holds that hepatic uptake
The Journal of Clinical Investigation

of CMs can occur only after these particles are shrunk by extrahepatic lipolysis into remnant lipoproteins that then become small
enough to squeeze through the approximately 100-nm fenestrae in
the endothelial lining of liver sinusoids. Yet most of the triglyceride-rich lipoproteins in plasma from hyperchylomicronemic mice
were reported to be less than 100 nm in diameter (90). Thus, there
must be a molecular, not just a physical, explanation for the robust
initial targeting of these particles to adipose tissue and striated
muscle under normal conditions.
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The answer appears to reside in the recent discoveries of 2
unsuspected participants in peripheral lipolysis: apoA-V on lipoproteins and the glycosylphosphatidylinositol-anchored (GPIanchored) HDL-binding protein 1 (GPIHBP1) on peripheral
endothelium. Adipocyte-specific knockout of a third molecule,
LDL receptor–related protein–1 (Lrp1), revealed a role in lipid
uptake from model CM remnants into brown fat, but not into
white fat (91), and so its relevance to human physiology remains
unclear at this point.
APOA5. In 2001, 2 laboratories discovered a new apoprotein gene
(dubbed APOA5, within the well-known APOA1/APOC3/APOA4
gene cluster) using a computational search for conserved genomic
regions and a survey of upregulated genes during liver injury; the
protein product is referred to as apoA-V or APOA5. To demonstrate
its relevance to lipoprotein physiology, Pennacchio et al. reported that mice transgenic for human apoA-V showed a two-thirds
reduction in plasma triglyceride levels; that Apoa5 knockout mice
exhibited 4 times the plasma triglyceride concentrations of control animals; and that human polymorphisms were significantly
associated with plasma triglyceride values (92). Subsequent studies
confirmed the link between human apoA-V variants and both fasting and postprandial hypertriglyceridemia (43, 47, 75, 93). Despite
its substantial effects, apoA-V exhibits surprisingly low levels in
normal plasma compared with other apoproteins (approximately
180 ng/ml, about 0.02% the level of apoA-I), which is why it was
missed in earlier compositional studies of lipoproteins. The normal apoA-V protein potently facilitates LpL-mediated triglyceride
hydrolysis in animals (94) and in humans (93). In addition, apoA-V
facilitates hydrolysis of triglyceride-rich lipoproteins by LpL in
solution or bound to HSPGs on the surface of cultured cells (94).
This last finding requires revisiting based on recent results concerning the second molecule, GPIHBP1 (Figure 3).
GPIHBP1. During a screen of hundreds of knockout mice at
Genentech, overly milky lipemia was unexpectedly noted in
mice lacking Gpihbp1 (90, 95), a GPI-anchored membrane protein originally identified by its ability to bind HDL (96). Subsequent characterization of adult Gpihpb1–/– mice by Beigneux et al.
indicated high plasma concentrations of large, triglyceride-rich
apoB48 lipoproteins in the CM/VLDL size range, low plasma levels
of HDL, and impaired CM removal (apparently owing to defective
lipolysis in peripheral tissues), but only about 40% reduction in
postheparin plasma LpL levels (90).
Mechanistic investigations of this phenotype led to the hypothesis
that Gpihbp1, not HSPGs, provides the key platform for LpL-mediated lipolysis of CM triglycerides on microvascular endothelium
(see “Integrated model for CM hydrolysis and local NEFA uptake”;
Figure 3; and refs. 90, 95). Expression of Gpihbp1 in vivo was
found exclusively on the luminal surface of endothelial cells, with
particularly high levels in the capillaries of adipose tissue and striated muscle (90). Consistent with a role in caloric delivery, Gpihbp1
mRNA levels in muscle were doubled by fasting (90), reminiscent
of the metabolic control of LpL discussed above (Table 1). Levels of
Gpihbp1 in liver are low, which likely contributes to poor hepatic
uptake of CMs until triglyceride hydrolysis transforms them into
remnant lipoproteins that display different binding epitopes.
In vitro, the transfection of HSPG-deficient cells with a Gpihbp1
expression construct caused robust, high-affinity binding of LpL
(Kd, 36 nM; ref. 90). For comparison, LpL binding to the HSPGs
on cultured endothelial cells exhibits a Kd of 140–520 nM (72),
which implies that Gpihbp1 could tear LpL away from endothelial
3254
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HSPGs after HSPG-mediated transcytosis (Figure 3). Transfection
of LDL receptor–deficient cells with a Gpihbp1 expression vector
increased their binding to artificial apoA-V/phosphatidylcholine
disks and to CMs harvested from Gpihbp–/– mice. In each case, the
interactions appear to be electrostatic: LpL, apoA-V, and other CM
apoproteins contain positively charged domains, and Gpihbp1
contains a highly negatively charged region toward its N terminus,
far from the plasma membrane. By binding both LpL and CMs,
Gpihpb1 may bring them physically together to facilitate lipolysis.
If LpL and CMs occupy the same negatively charged site on Gpihbp1, efficient lipolysis could require dimerization of Gpihbp1, a
process that may be facilitated by its Ly-6 domain (90).
The Gpihbp1–/– mouse is the second of only 2 examples of chylomicronemia related to a defect in the endothelium of adipose tissue and muscle (90, 97). Interestingly, a rare mutation in GPIHBP1
has been associated with human chylomicronemia, although this
variant appears to function normally in vitro (98). Further studies
are needed in order to definitively establish the role of GPIHBP1 in
human physiology, although it presumably serves functions similar to those of its murine homolog.
Integrated model for CM hydrolysis and local NEFA uptake
The known properties of these molecular participants suggest
that CM hydrolysis and local NEFA uptake are facilitated by being
concentrated within cholesterol-rich membrane microdomains
(rafts) along the luminal endothelial plasma membrane (Figure
3). The major HSPGs expressed by endothelial cells include the
syndecan family of transmembrane HSPGs and the glypican family of GPI-anchored HSPGs. We (99) and others (100) showed that
syndecan HSPGs move into rafts upon clustering. Binding just
a dimer, such as enzymatically active LpL, appears sufficient for
syndecan to localize into rafts (99). Importantly, GPI-anchored
proteins also move laterally into rafts upon clustering (101), and
so I expect that GPIHBP1 and glypican HSPGs would colocalize
with syndecans after transendothelial transport of active, dimeric
LpL. Close proximity should facilitate the transfer of LpL from
syndecan and glypican HSPGs onto higher-affinity binding sites
on nearby GPIHBP1 (Figure 3).
Efficient importation of newly released NEFAs by fat and muscle relies on CD36, a member of the class B family of scavenger
receptors that is expressed by adipocytes, myocytes, and microvascular endothelial cells. Adipose expression of Cd36 mRNA is
induced in vivo by high-fat feeding, apparently to facilitate fatty
acid uptake and storage (102). Adipose expression is also increased
in human type 2 diabetes (103), which likely accelerates the delivery of NEFA calories into this tissue and could worsen obesity
(Table 1). Importantly, the Cd36 fatty acid translocase localizes to
and requires rafts for long-chain fatty acid uptake into adipocytes
(104) and other cells, and I speculate the same is true for transendothelial NEFA transport (Figure 3). Again, close proximity
would facilitate molecular transfer, in this case, of NEFAs from
LpL–GPIHBP1–apoA-V/CM complexes onto CD36. Consistent
with this model, disruption of the murine gene for caveolin-1, a
scaffolding protein that is highly expressed in endothelial cells
and adipocytes and directs the formation of a specific class of
cholesterol-rich membrane microdomains, impairs lipolysis of
postprandial lipoproteins despite normal heparin-releasable LpL
activity (97). The caveolin-1 knockout also interferes with the
postprandial importation of NEFAs across endothelium into adipose tissue and thereby blocks the development of diet-induced
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Figure 4
Efficient hepatic uptake of CM remnant lipoproteins. Hepatic HSPGs exhibit extreme structural features of their carbohydrate side-chains that
enhance ligand binding. Thus, HSPGs in the liver rapidly pull apoB48 remnant lipoproteins out of plasma via interactions with positively charged
proteins on the particles, chiefly LpL and apoE. Once in the liver, the particles encounter hepatic lipase (HL), which serves as an additional bridging
molecule between HSPGs and lipoproteins. Shown are 2 pathways for particle clearance. The first is direct receptor-mediated uptake, in which
cholesteryl ester–rich apoB48 remnant lipoproteins pass from the hepatic sinusoid through the fenestrated endothelium and then bind directly to
integral plasma membrane receptors (red arrows; shown are the LDL receptor, which binds apoE, and the syndecan and glypican HSPGs, which
bind LpL, hepatic lipase, and apoE). The second clearance mechanism is a cooperative pathway, in which apoB48 remnant lipoproteins from the
hepatic sinusoid are first sequestered by matrix HSPGs within the space of Disse and then taken up in cooperation with the integral plasma membrane receptors (blue arrows; shown are the collagen XVIII and perlecan HSPGs). Also shown is one of several secreted enzymes (Enz), such as
heparanase or the heparan 6-O-endosulfatases, that are expressed by liver, degrade HSPGs, and may dampen these processes.

obesity (97). Likewise, mutation of human caveolin-1 is a cause of
dyslipidemia with lipodystrophy, which suggests that the same
processes occur in people (105).
CM catabolism: rapid hepatic uptake of apoB48 remnants
Over a quarter century ago, astute observations in vivo revealed that
efficient hepatic uptake of remnant lipoproteins from plasma does
not require LDL receptors (46, 106–108). This insight launched a
long, difficult search for the molecules responsible for this crucial
pathway. Over many years, several protein candidates were identified,
most notably LRP1 (109), but disablement of hepatic LRP1 in vivo
fails to result in poor clearance of remnant lipoproteins, particularly
when LDL receptors are present, as they are in normal human physiology (109–112). Instead, work from our laboratory (39) and others
(44, 45, 111, 113, 114) implicated HSPGs, contradicting a common
view that these molecules play only passive, structural roles (Figure 4
and refs. 40, 74). Extreme structural features of hepatic HSPGs that
enhance ligand affinity (89), noted above, direct remnants into the
liver. Moreover, strong evidence now exists for a physiologic role for
HSPGs in remnant lipoprotein clearance in humans (44, 45).
The Journal of Clinical Investigation

Because many HSPG core proteins are highly conserved, yet dissimilar from each other, we hypothesized that different classes of HSPGs
would mediate distinct endocytic pathways (Figure 4 and refs. 40, 74).
To date, we have demonstrated a specific endocytic pathway mediated by syndecan HSPGs when they become clustered (40, 99) and a
separate pathway with distinct subcellular trafficking mediated by the
perlecan HSPG when it is adherent to the cell surface (74, 115, 116).
Endocytosis via glypican HSPGs has also been reported (117).
Normal liver expresses several syndecans, the perlecan HSPG,
glypicans, the long variant of collagen XVIII, and agrin (Figure 4 and
refs. 118–120). The contribution of each of these HSPGs to remnant
lipoprotein uptake in vivo needs to be evaluated. Because syndecan-1
is particularly abundant on the sinusoidal surface of hepatic parenchymal cells (118), it is a strong candidate to participate in remnant
lipoprotein clearance in vivo (40). In this context, we proposed that
hepatic HSPGs can be divided into 2 functional subsets (39): those
that cells readily internalize, especially the integral plasma membrane syndecans (40) and glypicans (117), and those that cells might
not readily internalize, meaning extracellular HSPGs of the basement membrane and other matrix, such as collagen XVIII, agrin, and
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most of the perlecan within the liver. Thus, in our model, cell surface
syndecan and glypican HSPGs bind, then directly carry, remnant
lipoproteins and other ligands into the cells, whereas matrix HSPGs
bind and sequester their ligands; however, endocytosis requires
cooperation with cell surface receptors, particularly syndecan-1, the
LDL receptor (115), and possibly glypicans (Figure 4). Because syndecan-mediated endocytosis proceeds less rapidly (t1/2, about 1 h; ref.
40) than uptake via LDL receptors (t1/2, about 10 min), this model
may account for quick hepatic uptake of remnants from plasma
into the space of Disse, followed by continued internalization into
hepatocytes even when LDL receptors are absent, although the internalization occurs at a reduced speed (Figure 4 and refs. 46, 108).
Diabetes mellitus and related conditions have been reported
to cause CM overproduction (15, 67), delayed hydrolysis of CM
triglyceride in the periphery, and — perhaps most important to
the development of vascular disease — substantial impairment
in hepatic clearance of atherogenic CM remnants (4, 13, 67, 113,
121). Persistent remnants, unlike CMs themselves, readily enter
the arterial wall and are retained there (4), initiating and accelerating atherosclerosis (6, 11, 12, 122). Impaired hepatic clearance of
apoB48 remnants from plasma arises in large part from the failure
of diabetic liver to properly assemble HSPGs (113, 122–124). Specific molecular mediators of defective hepatic HPSG assembly in
diabetes include suppression of heparan sulfate N-deacetylase/Nsulfotransferase–1 (Ndst1) (122), a key enzyme in the biosynthesis
of highly charged, flexible heparan sulfate chains that avidly bind
ligands, and suppression of Fxr (125), an upstream regulator of
syndecan-1 expression (126). Liver-specific knockout of the same
heparan sulfate assembly enzyme, Ndst1, produces hypertriglyceridemia and a robust delay in the clearance of postprandial remnant
lipoproteins (111), an important observation that confirms the role
of HSPGs as remnant receptors (39) and the identification of Ndst1
as a key regulatory factor (Table 1 and ref. 122). Regarding reversibility, moderate caloric restriction of obese, type 2 diabetic mice
corrects their defect in remnant lipoprotein clearance (127), and
similar effects occur in human diabetic subjects after short-term
weight loss (128). This body of work provides tremendous explanatory power, elucidating the normal physiologic uptake of remnant
lipoproteins by the liver as well as the unhealthy persistence of these
particles in diabetes and related syndromes (Figure 4).
Finally, it has been hypothesized that molecules other than HSPGs
and LDL receptor family members may also contribute to hepatic
clearance of remnants, but their nature remains a matter of speculation (112). One candidate is scavenger receptor class B type I (Srb1),
proposed as a docking molecule in the liver for CM remnants (129).
Because conflicting literature indicates that the hepatic expression
of SRB1 may be up- or downregulated in diabetes, its contribution
to poor removal of remnants in that condition remains unknown.
Conclusions and future directions
The central question facing the field is how this explosion in
knowledge might benefit human health. Despite our extensive
1. Konstantinov, I.E., Mejevoi, N., and Anichkov,
N.M. 2006. Nikolai N. Anichkov and his theory of
atherosclerosis. Tex. Heart Inst. J. 33:417–423.
2. Weinstock, P.H., et al. 1997. Lipoprotein lipase
controls fatty acid entry into adipose tissue, but
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mice deficient in adipose tissue lipoprotein lipase.
Proc. Natl. Acad. Sci. U. S. A. 94:10261–10266.
3. Mead, J.R., Irvine, S.A., and Ramji, D.P. 2002. Lipoprotein lipase: structure, function, regulation, and
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molecular understanding, major health problems related to intestinal absorption of lipids and other overly abundant macronutrients — coupled with physical inactivity — continue to grow worldwide, particularly atherosclerosis, obesity, and type 2 diabetes.
Moreover, as noted throughout this review, many derangements
in lipid absorption and trafficking can be reversed by well-known
lifestyle changes and available pharmaceutical agents.
The situation could be improved by 2 general approaches.
The first is better implementation of recognized strategies.
Improvements in lifestyle can be facilitated by education and
counseling, but also by pancreatic lipase inhibitors (Table
2), novel appetite suppressants, and surgical techniques that
reduce food intake and body weight. New methods of lowering plasma concentrations of atherogenic apoB-containing
lipoproteins are also under development (11, 12). Public policy,
which is extensively reviewed elsewhere (80, 81), remains crucial
to promoting active living and the cultivation and consumption of affordable, healthy foods.
The second approach is the exploration of new therapeutic targets. Despite its importance, postprandial dyslipidemia has often
been overlooked because it remains inconvenient to accurately
assess. Improved apoB48-specific assays will likely help. Moreover,
nonfasting plasma triglyceride levels, an easy yet nonstandardized measurement related to postprandial dyslipidemia, correlate
with future cardiovascular events and could serve as a therapeutic target (4, 13). Novel points of control could be found through
additional molecular characterizations of fed/sedentary states as
well as characterization of the beneficial changes that occur during caloric restriction and exercise. For example, reversal of intestinal insulin resistance has not been explored; the molecular basis
for ezetimibe-resistant cholesterol absorption needs elucidation;
metabolic regulation of GPIHBP1 and its role in human biology
require further study; and improvements in hepatic clearance of
remnant lipoproteins upon weight loss remain completely uncharacterized on a molecular level.
There is no substitute for a combined approach. The exciting
opportunities outlined above for fundamental and translational
advances in the biology of lipid absorption and transport will require
an aggressive mix of new basic, clinical, and public policy efforts.
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